Glenmark Pharmaceuticals today said its investigational fixed-dose combination nasal spray, being studied for the treatment of seasonal allergic rhinitis, has shown positive results.
The results for GSP 301, a fixed-dose combination of mometasone furoate 25 mcg and olopatadine hydrochloride 665 mcg are from a recently completed phase III trial assessing its efficacy and safety versus mometasone, olopatadine or placebo, it said in a BSE filing.
The company's President and Chief Medical Officer Fred Grossman said: "We continue to advance our respiratory pipeline and are pleased to report positive results of GSP 301 in seasonal allergic rhinitis."
The US-based trial enrolled 1,176 adults and adolescents 12 years of age and older for 14-days of twice daily treatment with GSP 301.
The stock of the company was trading 0.24 per cent down at Rs 869.30 in the afternoon on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
